Work

Targeting the LINC00265/miR-485-5p axis for diagnosis and therapeutic intervention in breast cancer

Year: 2025

Type: article

Abstract: BACKGROUND: The incidence of breast cancer ranks first among female tumors. Early diagnosis and treatment of breast cancer can effectively alleviate the suffering of patients, and attention to breast cancer diagnostic markers may provide a new theoretical basis for biological therapy. PURPOSE: The objective of this study was to investigate the diagnostic value of LINC00265 in breast cancer and to elucidate its pathological mechanisms. METHODS: There were 88 breast cancer patients as the experimental subjects and 72 healthy individuals as the control group. LINC00265 and miR-485-5p levels in serum and cell supernatants were determined by RT-qPCR analysis. Cell function was evaluated via CCK-8 and Transwell assays. The sponge function of LINC00265 on miR-485-5p was confirmed by conducting a dual-luciferase activity assay. RESULTS: LINC00265 was highly expressed, and miR-485-5p was downregulated in breast cancer. LINC00265 has diagnostic value in breast cancer and is closely related to lymphatic metastasis and TNM stage in patients. Silencing LINC00265 suppressed cell function, while knockdown of miR-485-5p restored this regulation. CONCLUSION: Significantly upregulated LINC00265 is a biomarker for the diagnosis of breast cancer, and LINC00265 binds to miR-485-5p to mediate tumor progression.

Source: Discover Oncology

DOI: 10.1007/s12672-025-03811-6

Authors: Qiang Jiang, Suya Han, Ru Chang, Jianzhen Pan, Bingjie Zhang